Anna Rebecca Wolfson, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Hypersensitivity | 16 | 2024 | 903 | 3.610 |
Why?
|
| Anaphylaxis | 7 | 2023 | 738 | 1.550 |
Why?
|
| Skin Tests | 8 | 2024 | 630 | 1.320 |
Why?
|
| beta-Lactams | 5 | 2023 | 158 | 1.160 |
Why?
|
| Penicillins | 7 | 2024 | 403 | 1.100 |
Why?
|
| Urticaria | 3 | 2022 | 151 | 1.060 |
Why?
|
| Hypersensitivity | 6 | 2023 | 1168 | 1.040 |
Why?
|
| Histamine H1 Antagonists, Non-Sedating | 1 | 2022 | 16 | 0.820 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 372 | 0.650 |
Why?
|
| Vaccines | 2 | 2022 | 840 | 0.550 |
Why?
|
| Immunization | 1 | 2021 | 1218 | 0.530 |
Why?
|
| Hypersensitivity, Immediate | 3 | 2023 | 346 | 0.500 |
Why?
|
| Anti-Bacterial Agents | 11 | 2024 | 7473 | 0.400 |
Why?
|
| Excipients | 3 | 2023 | 96 | 0.290 |
Why?
|
| Skin | 1 | 2021 | 4482 | 0.280 |
Why?
|
| Vaccination | 4 | 2022 | 3431 | 0.210 |
Why?
|
| Diphenhydramine | 1 | 2022 | 61 | 0.200 |
Why?
|
| Histamine H1 Antagonists | 1 | 2022 | 100 | 0.200 |
Why?
|
| Histamine Antagonists | 1 | 2022 | 93 | 0.200 |
Why?
|
| Vaccines, Synthetic | 2 | 2022 | 620 | 0.190 |
Why?
|
| RNA, Messenger | 4 | 2023 | 12772 | 0.170 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2024 | 273 | 0.170 |
Why?
|
| Electronics, Medical | 1 | 2019 | 70 | 0.160 |
Why?
|
| Humans | 35 | 2024 | 766000 | 0.160 |
Why?
|
| Universities | 1 | 2023 | 1004 | 0.150 |
Why?
|
| Desensitization, Immunologic | 2 | 2020 | 545 | 0.140 |
Why?
|
| Edema | 1 | 2021 | 763 | 0.130 |
Why?
|
| Diagnostic Errors | 1 | 2024 | 1276 | 0.130 |
Why?
|
| Respiratory Sounds | 1 | 2021 | 702 | 0.130 |
Why?
|
| Allergens | 2 | 2021 | 1435 | 0.130 |
Why?
|
| Viral Vaccines | 1 | 2021 | 596 | 0.120 |
Why?
|
| Pregnancy | 4 | 2023 | 30227 | 0.120 |
Why?
|
| Students | 1 | 2023 | 1741 | 0.110 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2019 | 1177 | 0.100 |
Why?
|
| Qualitative Research | 1 | 2024 | 3138 | 0.100 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 1084 | 0.100 |
Why?
|
| Cesarean Section | 1 | 2020 | 1418 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 4 | 2022 | 7423 | 0.090 |
Why?
|
| Biological Products | 1 | 2021 | 947 | 0.090 |
Why?
|
| Electronic Health Records | 2 | 2019 | 4863 | 0.090 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 13634 | 0.090 |
Why?
|
| Female | 12 | 2024 | 396158 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2024 | 12975 | 0.080 |
Why?
|
| Anticonvulsants | 1 | 2018 | 1920 | 0.080 |
Why?
|
| Flavonoids | 1 | 2010 | 446 | 0.070 |
Why?
|
| Factor VIII | 1 | 2008 | 347 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2019 | 3617 | 0.060 |
Why?
|
| Health Care Costs | 1 | 2018 | 3240 | 0.060 |
Why?
|
| Length of Stay | 1 | 2018 | 6489 | 0.060 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 3229 | 0.060 |
Why?
|
| Adult | 7 | 2024 | 223106 | 0.050 |
Why?
|
| Polysorbates | 1 | 2022 | 46 | 0.050 |
Why?
|
| Pandemics | 1 | 2023 | 8724 | 0.050 |
Why?
|
| Inpatients | 3 | 2019 | 2565 | 0.050 |
Why?
|
| Endoplasmic Reticulum | 1 | 2008 | 1132 | 0.050 |
Why?
|
| Male | 9 | 2024 | 363855 | 0.050 |
Why?
|
| Piperidines | 1 | 2010 | 1663 | 0.050 |
Why?
|
| Telemedicine | 1 | 2019 | 3108 | 0.050 |
Why?
|
| Prevalence | 1 | 2018 | 15820 | 0.050 |
Why?
|
| Antioxidants | 1 | 2008 | 1671 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2024 | 81542 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 3885 | 0.040 |
Why?
|
| Eosinophilia | 1 | 2024 | 553 | 0.040 |
Why?
|
| Young Adult | 2 | 2023 | 59857 | 0.040 |
Why?
|
| Risk Factors | 2 | 2023 | 74838 | 0.040 |
Why?
|
| Middle Aged | 7 | 2024 | 223025 | 0.040 |
Why?
|
| Aged | 6 | 2024 | 171161 | 0.040 |
Why?
|
| Cephalosporins | 1 | 2019 | 200 | 0.040 |
Why?
|
| Allergy and Immunology | 1 | 2019 | 170 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 877 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2022 | 2352 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2021 | 1725 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2010 | 5695 | 0.030 |
Why?
|
| Consensus | 1 | 2023 | 3200 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2023 | 2646 | 0.030 |
Why?
|
| United States | 4 | 2024 | 72916 | 0.030 |
Why?
|
| Documentation | 1 | 2019 | 911 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 1673 | 0.020 |
Why?
|
| Self Report | 1 | 2023 | 3769 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2023 | 1877 | 0.020 |
Why?
|
| Outpatients | 1 | 2019 | 1595 | 0.020 |
Why?
|
| Animals | 2 | 2021 | 168775 | 0.020 |
Why?
|
| Ohio | 1 | 2010 | 320 | 0.020 |
Why?
|
| Protein Denaturation | 1 | 2008 | 240 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 895 | 0.020 |
Why?
|
| Cricetulus | 1 | 2008 | 807 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2010 | 1638 | 0.020 |
Why?
|
| CHO Cells | 1 | 2008 | 1373 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2024 | 22231 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 2227 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 5510 | 0.020 |
Why?
|
| Child | 1 | 2023 | 80567 | 0.020 |
Why?
|
| Cricetinae | 1 | 2008 | 2413 | 0.010 |
Why?
|
| Phenotype | 1 | 2022 | 16712 | 0.010 |
Why?
|
| Boston | 1 | 2017 | 9336 | 0.010 |
Why?
|
| Neoplasms | 1 | 2010 | 22336 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2008 | 3140 | 0.010 |
Why?
|
| Cytokines | 1 | 2010 | 7425 | 0.010 |
Why?
|
| Apoptosis | 1 | 2008 | 9507 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2008 | 22334 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2010 | 65199 | 0.000 |
Why?
|
| Mice | 1 | 2008 | 81821 | 0.000 |
Why?
|